It could be described as one-dimensional, head-in-the-sand analysis.
HER-VAXX failed for a lot of reasons, but it was originally a bad investment because Herceptin was dominating the market (1) and all the competitors trying to steal market share from Herceptin were being tested directly against Herceptin (2).
1. Oncologists treating cancer use what they know works. 2. Oncologists will not change unless there is unequivocal head-to-head proof something else is better.
Having a unique path to market is the most essential element to commercial success, which is why first-in-class drugs have performed the best commercially over the last 3 decades. Competing for market share is difficult to do. Keytruda was a massive commercial success because it was first and could be added to standard of care regimens.
Your man is about to pay the ultimate price for utter, biased ignorance. There is no clear commercialization strategy for Vaxinia or Oasis, and very little done for Azer-cel.
Vaxinia P2 initiation pushed back to 2026? Every investor here realises that management have direct access to open label cholangiocarcinoma expansion data with 3 patients treated since December. I believe that this is the early sign that the P2 is not going to get off the ground due to lack of efficacy and/or commercial opportunity.
IMU Price at posting:
3.6¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)